DSM expands its biomedical business with launch of its cellular therapy development services
The first product, developed by DSM and launched by DePuy Synthes Mitek Sports Medicine, concentrates platelets from whole blood in only two and a half minutes. The DePuy Synthes Mitek Sports Medicine PEAK™ Platelet Rich Plasma System yields a higher concentration of undamaged platelets and a more consistent output than existing devices on the market. Further, the device weighs only four pounds, making it easy to store in surgical specialty rooms as well as transport through a doctor’s office or hospital.
“DSM is in a position to help unleash the potential of autologous cellular therapies,” said Chad Smith, Director of Mechanical Devices at DSM Biomedical. “The emerging and fragmented field has been hamstrung by products that are difficult to use, time consuming, and inconsistent. Our distribution agreement with DePuy Synthes Mitek Sports Medicine signals the first step towards greater physician confidence in their tools. DSM looks forward to partnerships with major companies who seek to add cellular therapy devices to their portfolio.”
“DSM’s portfolio of regenerative materials includes collagen, extracellular matrices, bioceramics, polymers & metals, as well as device R&D services,” said Kristine Senft, Vice President of Regenerative Materials at DSM Biomedical. “We have many new developments in the pipeline that will further position DSM as an innovative leader paving the way for the future of medical technologies and materials.”
For more information about DSM’s cellular therapy development services please visit: www.dsm.com/medical/cellular-therapy-development-services